

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Fusen Pharmaceutical Company Limited

福森藥業有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1652)

VOLUNTARY ANNOUNCEMENT SELECTION RESULTS OF NATIONAL CENTRALISED MEDICINES PROCUREMENT

The board of directors (the “**Board**”) of Fusen Pharmaceutical Company Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that four of the Company’s products were selected in the tender results of the twelfth batch of the National Centralised Medicines Procurement (全國藥品集中採購) in China on 31 July 2026: Nicardipine Injection (2 ml: 2 mg, 5 ml: 5 mg), Azilsartan Medoxomil Potassium Tablets (40 mg, 80 mg), Compound Potassium Hydrogen Phosphate Injection (5 ml: containing 1.12 g of monopotassium phosphate and 1.18 g of dipotassium phosphate (calculated as K_2HPO_4)), and Dydrogesterone Tablets (10 mg).

This announcement is made by the Company on a voluntary basis for the purpose of keeping the shareholders and potential investors informed of the latest business developments of the Company.

By order of the Board
Fusen Pharmaceutical Company Limited
Mr. Cao Zhiming
Chairman and Executive Director

Hong Kong, 3 August 2026

As at the date of this announcement, the Board of the Company comprises Mr. Cao Zhiming (Chairman), Mr. Hou Taisheng, Mr. Chi Yongsheng and Ms. Meng Qingfen as executive Directors, and Mr. Lee Kwok Tung Louis, Dr. To Kit Wa and Mr. Yu Ho Ming as independent non-executive Directors.